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PIEWPOINT
re Drug-Eluting Stents the Preferred
reatment for Multivessel Coronary Artery Disease?
loyd W. Klein, MD, FACC
hicago and Melrose Park, Illinois
Drug-eluting stents (DES) constitute a major breakthrough in restenosis prevention after
initial percutaneous coronary intervention (PCI). Target lesion and vessel revascularization
rates of 10% at six months follow-up represent a significant medical advance. Many
cardiologists consider it reasonable to assume that PCI using DES ought to be considered
equivalent, if not superior, to bypass surgery. The argument made is that in previous
randomized clinical trials comparing PCI to coronary artery bypass grafting, restenosis was
the determining factor favoring surgery, an event that clinical experience suggests is no longer
as frequent. In the absence of a definitive clinical trial to support this view, how should the
prudent, cutting edge cardiologist evaluate the data and manage their patients? (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.057Cardiol 2006;47:22–6) © 2006 by the American College of Cardiology Foundation
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pInsanity: doing the same thing over and over again and
expecting different results.
Albert Einstein (1)
ercutaneous coronary intervention (PCI) surpasses coro-
ary artery bypass grafting (CABG) as the most frequent
evascularization modality for obstructive coronary disease
CAD). The application of PCI to multivessel CAD,
owever, has been limited by restenosis, which developed in
0% to 40% with balloon angioplasty and 20% to 25% in the
are-metal stent (BMS) era (2). As a consequence, CABG
as demonstrated to have better long-term outcomes than
CI with BMS and/or balloon angioplasty in two- and
hree-vessel CAD. The problem of stenosis recurrence is
specially relevant in diabetics, those with diffuse CAD, and
atients with chronic total occlusions, who comprise a large
roportion of patients with multivessel CAD that could
otentially be candidates for PCI rather than CABG.
Although restenosis rates have been steadily decreasing
ince the mid-1990s, the anti-proliferative drug-eluting
tents (DES) constitute a major breakthrough in restenosis
revention after initial PCI. Target lesion and vessel revas-
ularization rates of 10% at six months follow-up repre-
ent a significant medical advance. Because prior clinical
rials comparing PCI techniques versus CABG showed that
estenosis is the primary drawback, many interventionists
onsider it reasonable to assume that PCI with DES now
ught to be considered equivalent, if not superior, to bypass
urgery. The argument is made that, in previous randomized
linical trials comparing PCI to CABG, restenosis was the
etermining factor favoring surgery, an event that clinical
xperience suggests is no longer as frequent. In the absence
f a definitive clinical trial to support this view (although
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ccepted August 2, 2005.uch trials are being organized at this time) how should the
rudent, cutting-edge cardiologist evaluate the data from
he studies that are currently available?
HE TARGET: CABG
or PCI to replace CABG as preferred therapy in multives-
el CAD, clinical trials must demonstrate that long-term
utcomes are at least equivalent. The challenges that must be
vercome include restenosis and the inability to treat chronic
otal occlusions and small vessels with diffuse disease, particu-
arly in diabetics. Coronary artery bypass grafting has provided
reater durability (3) and more complete revascularization than
CI in the past. In general, the more diffuse the CAD, the
ore compelling the choice of CABG, particularly if left
entricular function is depressed, whereas patients with less
iffuse disease and focal lesions are traditionally considered
ood candidates for PCI (2).
Few cardiologists are satisfied with that conclusion. The
esire to refer fewer patients to CABG and offer as many as
ossible the advantages of PCI is appealing to many. There
as been an overall average increase of 17.3% in the
ncidence of PCI from 72.0 of 10,000 Medicare beneficia-
ies to 89.3 of 10,000 Medicare beneficiaries over three years
arlier this decade. Simultaneously, CABG procedure inci-
ence rates have been declining slightly (51.0 of 10,000 to
9.2 of 10,000) (4). The angiographic and clinical charac-
eristics of those undergoing PCI have markedly changed,
ith far more complex cases being treated by PCI despite no
iscernible decrease in outcomes. Drug-eluting stents di-
inish restenosis to less than double digits in simpler cases,
aising the possibility that perhaps it would be useful also in
omplex CAD cases. If so, this approach would be signifi-
antly cost effective compared to CABG, especially with the
ossibility of increased utilization of stenting in diabetics,
maller diameter vessels, and multivessel CAD (5,6).
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he fact that these trends exist despite clinical trial and
egistry data which show that CABG has excellent out-
omes highlights the problem of translating scientific evi-
ence to clinical practice. The underlying issue is that both
andomized trials and registries have inherent shortcomings.
ven well designed randomized trials may be obsolete on
ompletion because of shifting targets due to rapid techno-
ogic progress (e.g., BMS vs. DES). Then, trial designs may
ot conform to decision-making in clinical practice, render-
ng their conclusions difficult to apply and subject to debate.
inally, when the outcomes conflict with preconceived
otions, the tendency is to question their relevance on
rounds of design or analytic flaws.
The initial clinical trials testing the efficacy of DES versus
MS (7–9) evaluated their utility primarily in simple, short,
ingle lesions. While this trial design was successful in
emonstrating the benefit of DES compared to BMS, it
lso raised questions about their true efficacy in the kinds of
esions that are treated in every day clinical practice, because
nly a small percentage of cases involve the type A,
traightforward lesions treated in these trials. For example,
iabetics were included but only as an underpowered subset.
ifurcation lesions were mainly excluded; the presence of
hrombus was an exclusion criterion, as were long lesions.
onsequently, clinical studies evaluating the incidence of
ate stent thrombosis came well after hundreds of thousands
f patients had received the device and suggest that bifur-
ations and overlapping multiple stents may be problematic.
Randomized trials are underway to evaluate whether
ES provide outcomes similar to CABG in multivessel
AD when technically feasible. It is important to note that
nterventional cardiology has traveled down this road before,
n fact, twice. Randomized trials of balloon angioplasty
ersus CABG in multivessel CAD were undertaken in the
arly and mid-1990s; the results were disappointing but
emonstrated how much progress had been made and what
eeded to be done in the future (10–14). Although survival
as roughly similar regardless of initial revascularization pro-
edure, more angina, less functional improvement, and the
eed for repeat procedures were more frequent in the PCI
atients. One important exception was the diabetic patient,
Abbreviations and Acronyms
ARTS  Arterial Revascularization Therapies Study
BMS  bare-metal stent
CABG  coronary artery bypass grafting
CAD  coronary artery disease
DES  drug-eluting stents
ERACI  Argentine Randomized Trial of Percutaneous
Transluminal Coronary Angioplasty versus
Coronary Artery Bypass Surgery in
Multivessel Disease
PCI  percutaneous coronary interventionn whom survival was reduced if PCI was performed as the pnitial revascularization procedure (10–12). Later, the in-
roduction of BMS appeared to alter the restenosis rate
ufficiently to try again in the late 1990s. However, the
nterventionists’ optimism again was premature; despite less
ost and equal protection with respect to death and myo-
ardial infarction, the higher repeat revascularization rate
nd less relief of angina persisted (15–17). A recently
ublished registry supports this conclusion, although the
ata have been incorrectly interpreted as applicable to the
urrent generation of stenting (18).
An excellent example of a registry that appropriately
eflects case selection in clinical practice is the Arterial
evascularization Therapies Study (ARTS)-II trial, which
as presented at the American College of Cardiology
onvention in March 2005 (19). A total of 607 patients
reated with sirolimus stents were enrolled in a non-
andomized registry. The outcomes of these patients were
ompared to the CABG (n  602) and BMS arms (n 
00) of ARTS-I (16). In the ARTS-II trial, patients were
ore frequently diabetic (26.2% vs. 18.2%), had more
hree-vessel CAD (54% vs. 28%), and had more C-type
esions (13.9% vs. 7.5%) compared to the ARTS-I trial.
here was no difference in the major cardiovascular events
t one year between the ARTS-II DES trial registry
atients and CABG randomized patients in the ARTS-I
rial (10.4% vs. 11.6%), and there was no difference in any
ther outcome. This study is widely interpreted as suggest-
ng that current generation DES have similar outcomes as
ABG; however, its non-randomized nature and compar-
son with a non-concurrent CABG group leaves the ques-
ion open.
On the other hand, the results of Comparison of a
olymer-Based Paclitaxel-Eluting Stent with a Bare-metal
tent in Patients with Complex Coronary Artery Disease
TAXUS-V) could be interpreted more equivocally (20).
he primary end point, target vessel revascularization for
schemia at nine months, was diminished in the paclitaxel
tent group compared to BMS (12.1% vs. 17.3%, p 
.018). However, there was a higher rate of major adverse
ardiac events in the subgroup of 379 patients who received
ultiple stents (8.3% vs. 3.3%, p  0.047), and overlapping
tents were considered a risk factor for worse outcomes. An
ncreased likelihood of adverse events was associated with
ide branch narrowing and closure (p 0.03) and decreased
hrombolysis In Myocardial Infarction flow grade (p 
.02) with the DES. How these factors might manifest in a
linical trial versus CABG is speculative at this time.
The problems of subacute and late stent thrombosis,
owever, could clearly impact such a comparison. A further
all for caution is sounded in this issue of the Journal.
odriguez et al. (21) from the Argentine Randomized Trial
f Percutaneous Transluminal Coronary Angioplasty versus
oronary Artery Bypass Surgery in Multivessel Disease
ERACI) III trial report an incidence of stent thrombosis of
.1% in the 18 months after stent implantation in 225
atients with multivessel CAD. The authors report three
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Drug-Eluting Stents and Multivessel CAD January 3, 2006:22–6ases of stent thrombosis in the first month, three others in
he first year, and one additional case two and a half years
fter stent placement. In the patients who experienced this
omplication, associated with discontinuation of anti-
latelet therapy, six had an ST-segment elevation myocar-
ial infarction, and three died. This report follows a recent
erman and Italian study (22) that also highlighted the
roblem of stent thrombosis. A total of 2,229 consecutive
real-world” patients underwent successful DES implanta-
ion at three European hospitals over a 21-month period. At
ine-month follow-up, 29 patients (1.3%) had suffered stent
hrombosis, including 14 patients with subacute thrombosis
0.6%) and 15 patients with late thrombosis (0.7%). Among
hese 29 patients, 13 died. There was no difference in
ncidence between sirolimus or paclitaxel stents.
The critical role of how efficacious DES are in the
iabetic subgroup is underappreciated (23). The fact is that
f a target vessel revascularization rate of 10% to 15%
xists in the diabetic population, it would be statistically
mpossible to prove a benefit versus CABG. However,
edicated trials and subgroup analyses of larger studies, do
how revascularization rates approaching this magnitude. In
SAR-Diabetes, for example, the target lesion revascular-
zation rate at 9 months was 12.2% with Taxus and 6.4%
ith Cypher.
HE BIAS OF CARDIOLOGISTS
here are several reasons why cardiologists are seduced
epetitively into thinking that things have changed. In large
art, we are victims of enthusiasm about our craft. We know
he advantages of PCI to patients and the health care
ystem. We want to be persuaded by the outstanding results
f clinical trials and registries that the corner has been
urned. Although the presentations of the studies are
cientifically valid, and are delivered by outstanding inves-
igators and interventionists who strive to accurately portray
he limitations of each study, their sincere and honorable
assion for finding the new device or approach that will
olve this problem are difficult to ignore.
On the other hand, although skepticism is healthy, it also
ay be blinding! To recognize when a real advance has been
chieved, it is crucial that outstanding investigators publish
heir non-randomized observations periodically so that we
an accurately gauge the current status of the field.
It is also essential to recognize that cost factors into this
ssue more than most physicians acknowledge. The fact is
hat cost savings is an important component of the attrac-
iveness of a percutaneous approach to multivessel CAD.
he utilization of DES was expected to result in conversion
f some CABG procedures to PCI, shifting some resource-
ntensive patients into less expensive therapy and expand the
ercutaneous treatment option. An initial formal analysis by
ohen et al. (6) suggested that DES are cost-effective in
atients estimated to have a clinical restenosis rate greater
han 12% to 14%. These calculations were strongly depen- sent on the price of DES, which has decreased substantially
ince the publication of these evaluations, and reimburse-
ent, which also has improved. Rao et al. (23) recently
eported on the difficulties that were experienced in increas-
ng the utilization of these devices after their introduction.
any of the original economic assumptions made by third
arty payers and commercial interests were faulty and took
ime to correct (5).
Replacing CABG as the preferred therapy for two- and
hree-vessel CAD would not only save patients’ pain and
oss of productivity, but also money. Because the reimburse-
ent rate for CABG and PCI with DES differ by
$15,000, conversion of even a modest proportion of
ABG procedures to PCI would have a favorable impact on
ealth expenditures (4). While the expected rate of such
onversion was difficult to project, at least one retrospective
tudy suggested that a 21% conversion rate might be
xpected within one to two years after the introduction of
ES (25). Assuming these estimates are accurate, the
otential economic benefit to society is many hundreds of
illions of dollars yearly.
Consequently, Medicare agreed before DES were re-
eased to pay an additional base amount of approximately
1,800 over and above the BMS procedure reimbursement
ate. This level of reimbursement was determined on the
asis of calculating that profit (for Medicare) would be
ttained when the average number of DES per procedure
eached 1.8 and the conversion from BMS and CABG were
ver 80% and 15%, respectively (4); Medicare determined
hat health care expenditures would decrease if DES were
idely adopted and converted 15% of CABG to multivessel
CI. However, they failed to recognize that under this
eimbursement scheme, PCIs involving 2 DES would
ctually lose money for most hospitals. Hence, the calcu-
ated reimbursement level did not reward conversion to
ES and actually served as an impediment to its utilization
5,6,24). The improved price of these products since their
ntroduction resulting from competitive forces has favorably
ltered the economic equation.
URRENT STATE-OF-THE-ART
everal recent studies suggest, however, that although car-
iologists want to believe that DES ought to be the
referred therapy, there may be serious concerns, aside from
estenosis, which have not been sufficiently considered in
he past. Certainly the issue of vulnerable plaque progres-
ion has received substantial emphasis over the past few
ears. The antiquated notion of predicting the likelihood of
coronary stenosis demonstrated at coronary angiography
o progress to cause a myocardial infarction is no longer
enable. Yet despite the fact that rapid progression of a
ulnerable stenosis due to plaque rupture and acute throm-
osis is an accepted principle, clinically we still practice as if
he “high grade” stenosis requires urgent attention while less
ignificant luminal obstructions can be treated less aggres-
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January 3, 2006:22–6 Drug-Eluting Stents and Multivessel CADively. In part, this discrepancy is the product of a lack of
echnology that allows us to identify the vulnerable plaque
efore it ruptures. Also, we do not yet completely under-
tand how commonly plaque ruptures, in what time frame,
r with what consequences. Finally, we are not sufficiently
nowledgeable as to the risk:benefit ratio of current medical
nd procedural therapies to know what direction to take,
ven if we could reliably identify such lesions.
The communications from the ERACI III trial (21) and
he European registry (22) discussed above suggesting that
tent thrombosis may occur at a higher rate than usually
ppreciated should be of concern to those advocating a
ead-to-head comparison at this time. If the actual rate of
tent thrombosis causing myocardial infarction in the first
ear is on the order of 1% to 3% as reported in these trials,
t is difficult to conceive of how the hard numbers in any
linical comparison could favor PCI.
Perhaps the most disquieting new observation is that the
ncreased need for repeat interventional procedures, either at
he same site or within the same vessel(s), is not entirely
elated to restenosis at the site of the previous obstruction
nd the stent placed as treatment. The recent National
eart, Lung, and Blood Institute Dynamic Data registry
26) presented an elaborate analysis strongly suggesting that,
n the current stenting era, progression of disease may be the
mperative concern. The authors evaluated the rate of
rogression of non-target lesions over one year after PCI.
he authors reported that 6% of lesions thought not to be
ignificant enough to be addressed by PCI had progressed
ver that time frame to become clinically relevant. Impor-
antly, the data appear to suggest that the least favorable
utcomes with PCI are associated with extensive severe
AD. Hence, in large measure, it is the patient with
ultivessel CAD at most hazard of rapid, early progression
27). Both PCI and CABG are effective therapies in the
outine case, but those patients with diffuse, extensive
isease and those most difficult to treat with PCI in the
ast—the elderly, the diabetic, the chronic renal patient—
re the subset of patients with whom the future of this
ontroversy rests. That is not a prospect thoughtful inter-
entionists ought to relish (23).
To the extent to which these considerations are applicable
o everyday clinical practice, it is possible that multiple
tents of any design may have an inherent limitation when
pplied in complex CAD patients. Perhaps CABG succeeds
recisely because of its imprecision: stents treat only the
ocal area of most significant occlusion while CABG may
ypass the vulnerable plaques that could potentially develop
nto culprit lesions over time. Statin agents and other
harmacologic therapies that passivate vulnerable plaque
nd diminish inflammation may be just as important long-
erm as stents are short-term. As adjuncts of PCI or as a
tand-alone treatment strategy, the power of medical ther-
py should not be ignored.
These observations run counter to the prevailing attitudesbout the potential of DES, and accurate interpretation of
1linical trial data will be the subject of much discussion and
ebate. Although one can hope that head-to-head trials this
ime will lead to a different result than in the past (23), it is
ital in the interim to be cognizant of available information
hat suggests that the result of such trials is not a foregone
onclusion. The disconcerting possibility is that the funda-
ental challenge ahead may lie with the patient’s disease,
ot the physician’s cure.
DDENDUM
ince this paper was submitted, Ortolani et al. (28) reported
randomized trial demonstrating that diabetics undergoing
ES for focal lesions in small vessels (mean, 2.1 mm
iameter) had an angiographic restenosis rate of 25%.
lthough this was significantly better than with BMS (63%,
 0.002), nevertheless, the clinical MACE rate at eight
onths was 14%. At the American Heart Association
eeting in November, Macaya et al. (29) presented the
esults in the diabetes subset of the ARTS II trial. At one
ear, there was a revascularization rate of 12.6% in the
ES-treated patients versus 4.2% in the CABG patients.
hese studies further suggest that the diabetic patient may
ontinue to represent a serious challenge to catheter-based
nterventions.
eprint requests and correspondence: Dr. Lloyd W. Klein,
ottlieb Memorial Hospital, Professional Office Building Suite
314, 675 West North Avenue, Melrose Park, Illinois 60160.
-mail: lloydklein@comcast.net.
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